The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...
The U.S. Food and Drug Administration ( FDA) has approved the use of a nasal spray as a standalone treatment for major depressive disorder, offering a new option for those struggling with ...
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it ...
FDA approves Spravato as the first monotherapy for adults with major depressive disorder unresponsive to two oral ...
The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...
The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone ...
Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand-alone therapy for adults with treatment-resistant ...
Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...
Share on Pinterest The FDA has approved an esketamine nasal spray for the treatment of depression cases that do not respond to other therapeutic approaches. Image credit: Koldunov/Getty Images.